Document is current

Article History

Received: 7 May 2020

Accepted: 23 August 2020

First Online: 14 October 2020

Compliance with ethical standards

:

: M.E.C.: Advisory board and speaker honoraria—Ipsen, Novartis, AAA, ITM and Pfizer. M.P.: Honoraria for presentation and advisory boards—Ipsen; research grants—Ipsen to former institution (Charité University Medicine, Berlin). A.T.P.: Research funding—Ipsen, Sanofi and Incyte; consulting/advisory fees—Ipsen and Roche; speaker fees—Lexicon, Novartis and Ipsen. JBC: Research funding and travel grant—Ipsen. E.S.: Travel grants and speaker fees—Ipsen and Novartis. E.M.W.: Consultancy/advisory fees—Ipsen, Novartis, Lexicon and Progenics. P.R.: Research funding—Ipsen; speaker fees – Ipsen, Novartis, AAA, ITM; consultancy—Ipsen, Novartis, AAA, ITM. X-MTT: Ipsen employee.

: The study was conducted under the provisions of the Declaration of Helsinki [], and in accordance with the International Conference on Harmonisation Consolidated Guideline on Good Clinical Practice []. The study also adhered to all local regulatory requirements. Protocol amendments after the start of the study.

: Informed consent was obtained from all patients before enrolment into the OLE, prior to any study-specific procedures.